Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of dapagliflozin on endothelial progenitor cells and vascular lesions in type 2 diabetes mellitus
ChiCTR2200065869Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Chengdu Medical College
- Start
- Nov 2022
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of dapagliflozin and dulaglutide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by The First Affiliated Hospital of Chengdu Medical College. Primary endpoints: Number of endothelial progenitor cells in peripheral blood, Carotid intima-media thickness and 1 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
dapagliflozindulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2200065869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065869.